Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Dow
Merck
Boehringer Ingelheim
Baxter

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for BGJ398

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug BGJ398?

BGJ398 is an investigational drug.

There have been 17 clinical trials for BGJ398. The most recent clinical trial was a Phase 2 trial, which was initiated on December 31st 2018.

The most common disease conditions in clinical trials are Neoplasms, Melanoma, and Urinary Bladder Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Array BioPharma, and Memorial Sloan Kettering Cancer Center.

There are thirty-six US patents protecting this investigational drug and five hundred and nine international patents.

Recent Clinical Trials for BGJ398
TitleSponsorPhase
FGFR Inhibitor in FGFR Dysregulated CancerLung Cancer Group ColognePhase 2
Study of Oral Infigratinib in First Line Cholangiocarcinoma With FGFR2 Gene Fusion/TranslocationsQED Therapeutics, Inc.Phase 3
BGJ398 for the Treatment of Tumor-Induced OsteomalaciaNational Institute of Dental and Craniofacial Research (NIDCR)Phase 2

See all BGJ398 clinical trials

Clinical Trial Summary for BGJ398

Top disease conditions for BGJ398
Top clinical trial sponsors for BGJ398

See all BGJ398 clinical trials

US Patents for BGJ398

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGJ398   Start Trial FGFR inhibitor for use in the treatment of hypophosphatemic disorders Novartis AG (Basel, CH)   Start Trial
BGJ398   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
BGJ398   Start Trial Pharmaceutical combinations Novartis AG (Basel, CH)   Start Trial
BGJ398   Start Trial Deuterated triazolopyridazine as a kinase modulator Janssen Pharmaceutica NV (Beerse, BE)   Start Trial
BGJ398   Start Trial Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH)   Start Trial
BGJ398   Start Trial Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BGJ398

Drugname Country Document Number Estimated Expiration Related US Patent
BGJ398 Australia 2013241664 2032-03-30   Start Trial
BGJ398 Canada 2866229 2032-03-30   Start Trial
BGJ398 China 104321058 2032-03-30   Start Trial
BGJ398 China 109718239 2032-03-30   Start Trial
BGJ398 European Patent Office 2830626 2032-03-30   Start Trial
BGJ398 India 8969DEN2014 2032-03-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Merck
AstraZeneca
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.